glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Updated evidence on cardiovascular and renal effects of agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives | Cardiovascular Diabetology The rationale, design and baseline

Our findings suggest that tirzepatide, through its dual GIP/GLP-1 action, may be superior as a non-IOPlowering adjunct or even as a primary preventive agent in glaucoma management among patients with diabetes, the researchers wrote in their paper

Where Options Data Suggests LLY Shares Are Headed According to Barchart, options pricing signals continued momentum ahead

Hunger increases, fighting the peptide

It's especially appealing if you want flat-rate pricing that never increases with dose changes, plus 24/7 weight-loss coach access included at no extra charge

I felt so accomplished that I did something I set out to do

Cholesterol, glucose and insulin levels, liver fat, and blood pressure all appear to improve with these medications